StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
TPSTBullishEarningsnews
High materiality8/10

Tempest Advances TPST-4003 with Senlang Collaboration, Targets 2026 Dosing

Aug 13, 2026, 4:27 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Near-term TPST catalysts (TPST-4003 dosing, Senlang China trial, AGCTC manufacturing support) could drive upside despite liquidity risk; TPST-2003 interim efficacy supports upside if validated, though small cohorts limit durability.

AI summary

What happened, with direct paths to the underlying reporting

Tempest Therapeutics disclosed a collaboration with Hebei Senlang Biotechnology to advance TPST-4003, with first patient dosing expected in Q4 2026 and initial data in H1 2027. The company also highlighted TPST-2003 interim results showing 100% complete responses in 15 evaluable patients and a China-focused BD push, while cash runway remains tight and capital needs persist.

  • TPST-4003: CD19/BCMA CAR-T via CD7 mRNA/LNP; first patient dosing Q4 2026.
  • Senlang collaboration to run ~10-patient China trial in MG/MS; first patient Q4 2026.
  • TPST-2003 interim: 100% CR in 15 efficacy-evaluable patients; favorable safety.
  • Q2 cash shows $0.8m; cash burn rising; asset acquisition and warrants affected liquidity.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event